| Summary: | 碩士 === 國立臺北大學 === 企業管理學系 === 105 === The purpose of this research is to investigate the relationship between the volume of clinical studies and the volume of sales of specialty drugs and common chronic diseases drugs after NHIA (National Health Insurance Administration) reimbursement. For specialty drugs, two Epidermal Growth Factor Tyrosine Kinase Inhibitor(EGFR-TKIs), Iressa and Tarceva for Adenocarcinoma were selected and for common chronic disease, three Statins for hyperlipidemia were selected in this research. We analyzed the relationship between the volume of clinical studies published and their volume sales after reimbursement. The results showed that for specialty drugs, EGFR-TKIs, the volume of clinical studies was significantly correlated with the volume sales(r=0.722, p=0.000) but we found no correlation(r=0.189, p=0.376) for common chronic disease drug Statins .Although there are a lot of limitations of this research, our research suggested that pharmaceutical companies should continue to invest resources in conducting Phase IV clinical studies particularly for specialty drugs, not only for generating evidence for physicians to guide their clinical practices but also generate more consumptions and revenue by expanding more patients suitable for the medications with substantial evidence support.
|
|---|
